

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
PACIFICO Yokohama Conference Center	Room 1 Main Hall (1F)				Opening Ceremony		LS-01 Otsuka Pharmaceutical Co., Ltd.	History Session The interesting history of neurology			AO-01 Oral Presentation Award Nominee Session (Basic Research)					
	Room 2 301 (3F)				Symposium 01 Gut-brain axis in Neurodegeneration and inflammation		LS-02 CHUGAI PHARMACEUTICAL CO., LTD.	Symposium 06 MS/NMOSD revisited for future personalized treatments								Get Together Date & Time : May 20 (Wed), 19:00- Place : 3F "301-304", PACIFICO Yokohama Conference Center (Room 02-05)
	Room 3 302 (3F)						LS-03 AbbVie GK									
	Room 4 303 (3F)				Symposium 02 The usefulness of clinical neurophysiology for functional neurological disorders		LS-04 Eisai Japan / Biogen Japan	Symposium 07 Understanding New-Onset Refractory Status Epilepticus (NORSE)								
	Room 5 304 (3F)						LS-05 Tanabe Pharma Corporation									
	Room 6 311+312 (3F)						LS-06 Biogen Japan					O-01 Neuropathy				
	Room 7 313+314 (3F)						LS-07 Ono Pharmaceutical Co., Ltd.					O-02 Muscle disease 1				
	Room 8 315 (3F)								Hot Topics 02 Upgrade therapies for ischemic stroke			O-03 Cerebrovascular disease 1				
	Room 9 414+415 (4F)						LS-08 PDRadiopharma Inc.		Hot Topics 03 Atypical Parkinsonism: Approaches to Innovative Therapies			O-04 Parkinson's disease 1				
	Room 10 416+417 (4F)				Symposium 03 Autoimmune Nodopathies: Current Understanding, Future Perspectives, and Challenges		LS-09 Meiji Seika Pharma Co., Ltd.	Symposium 08 Genetic Insights into ALS: Unraveling Pathogenesis and Exploring Therapeutic Targets				O-05 Motor neuron disease 1				
	Room 11 418 (4F)						LS-10 TSUMURA & CO.	Symposium 09 Second career as a neurologist				O-06 Cerebellar ataxia · Spastic paraplegia 1				
	Room 12 419 (4F)				Hot Topics 01 Futuristic Rehabilitation through Cell Therapies and Biointegrated Devices: Japan Leading the Way		LS-11 Pfizer Japan Inc.	Symposium 10 Post-Transcriptional Regulation Pioneering the Future of Neurological Disease: Insights into Pathogenesis and Therapy				O-07 Neuroscience				
	Room 13 501 (5F)				Symposium 04 Not worn out! — Learning about "flexible aging" from brain images of super-elderly people —		LS-12 Novartis Pharma K.K.	LM-01 Lecture Marathon 01	LM-02 Lecture Marathon 02			O-08 Neuroimmunology 1				
	Room 14 502 (5F)						LS-13 UCB Japan Co.,Ltd.	Symposium 11 Current Status of Neurophysiology and its Application to Clinical Practice ~Focusing on the Basal Ganglia and Cerebellum~				O-09 Dementia 1				
	Room 15 503 (5F)				Symposium 05 Vitamin, Nutrition, and Exercise in Dementia		LS-14 Eli Lilly Japan K.K.	New Guideline 01 Advances in Dementia Management through Guidelines				AO-02 Oral Presentation Award Nominee Session (Clinical Research)				
Poster Session	Hall B (1F)			Poster Preparation / Poster Viewing				Poster Viewing				Poster Presentation / Discussion		Poster Removal		
Exhibition				Exhibition												



...On-demand streaming session

Plenary Session

Scientific Program

Educational Session

Free Papers (Oral)

Social Event

English Session

Simultaneous Interpretation

Web Live Streaming Session

PACIFICO Yokohama Conference Center	Room 1	Main Hall (1F)
	Room 2	301 (3F)
	Room 3	302 (3F)
	Room 4	303 (3F)
	Room 5	304 (3F)
	Room 6	311+312 (3F)
	Room 7	313+314 (3F)
	Room 8	315 (3F)
	Room 9	414+415 (4F)
	Room 10	416+417 (4F)
	Room 11	418 (4F)
	Room 12	419 (4F)
	Room 13	501 (5F)
	Room 14	502 (5F)
	Room 15	503 (5F)
Poster Session	Hall B (1F)	
Exhibition		

	7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Room 1		Web Symposium 12 ICAD and RNF213-Related Vasculopathy in East Asia			Web PL-01 Plenary Lecture 01 Speaker: Josep Dalmau Chair: Takahiro Iizuka	LS-15 Eisai Japan / Biogen Japan		Web Pr President Lecture Speaker: Kazutoshi Nishiyama Chair: Fumihiko Sakai	Web JSN Awards Ceremony Japanese Society of Neurology 2025 Award Winner Lecture	Web 2026 Special Symposium 01 Envisioning the Future of the Japanese Society of Neurology					
Room 2		Symposium 13 ALS and lipid metabolism abnormalities: pathophysiological analysis for treatment strategies and iPS cell drug discovery		O-10 Motor neuron disease 2		LS-16 Novartis Pharma K.K.								ES-01 Eli Lilly Japan K.K. / Daiichi Sankyo Co., Ltd.	
Room 3		Web Symposium 14 The cutting edge strategies for management of breakthrough stroke		O-11 Cerebrovascular disease 2		LS-17 UCB Japan Co., Ltd.				Web Symposium 20 Principles and Practice of Preventive Neurology: a rapidly burgeoning field of Neurology					
Room 4		Symposium 15 Migraine pathophysiology: An in-depth analysis		O-12 Parkinson's disease 2		LS-18 AbbVie GK				Symposium 21 Neurology meets Pharmacogenomics (PGx)					
Room 5				O-13 Clinical neurophysiology		LS-19 Alexion Pharma GK									
Room 6				O-14 Neuroradiology, Functional image		LS-20 GlaxoSmithKline K.K.								ES-02 CHUGAI PHARMACEUTICAL CO., LTD.	
Room 7						LS-21 Medical Affairs, Lundbeck Japan K.K.								ES-03 ONO PHARMACEUTICAL CO., LTD.	
Room 8		Symposium 16 State-of-the-Art Insights into the Pathogenesis of Repeat-Associated Muscle Diseases		O-15 Dystonia/ Involuntary movement		LS-22 CHUGAI PHARMACEUTICAL CO., LTD.				Hot Topics 06 Clinical Neurorehabilitation: A quarter century of progress and future outlook				ES-04 Novartis Pharma K.K.	
Room 9		Hot Topics 04 Frontiers in the Treatment of Spinocerebellar Degeneration - From Rehabilitation to Clinical Trials		O-16 Cerebellar ataxia · Spastic paraplegia 2		LS-23 SCRUM Inc				Hot Topics 07 The Future of Gene Editing in Neurological Disease Therapy: From CRISPR to Japan-Originated Technologies at the Forefront of Research				ES-05 PDRadiopharma Inc. / The Japanese Council of Nuclear Neuroimaging / Japanese Society of Nuclear Medicine	
Room 10		Web Symposium 17 Do neurologic diseases start at the autonomic nerves?		O-17 Parkinson's syndrome		LS-24 FP Pharmaceutical Corporation				Web Symposium 22 How to access and treat gait disorders				ES-06 Japan Blood Products Organization	
Room 11		Symposium 18 Advances in Inherited Peripheral Neuropathies: Latest Findings in Molecular, Clinical, and Pathological Research		O-18 Neurogenetics		LS-25 Novo Nordisk Pharma Ltd.				Symposium 23 Exploring the pathomechanism of neurological diseases from the perspective of endoplasmic reticulum function - From basic science to human neuropathology -					
Room 12		Meet the Expert Meet the AAN President: Emerging Leadership in Neurology - Perspectives from Young and Female Physicians		O-19 Neuroinfection		LS-26 Alnylam Japan K.K.				LB Late Breaking Symposium					
Room 13		LM-03 Lecture Marathon 03	LM-04 Lecture Marathon 04	O-20 Neuroimmunology 2 (MS · NMO)		LS-27 Eli Lilly Japan K.K.				LM-05 Lecture Marathon 05	LM-06 Lecture Marathon 06			ES-07 Eisai Co., Ltd.	
Room 14		New Guideline 02 Clinical practice guidelines for HTLV-1-associated myelopathy 2025		O-21 Dementia and related pathologies		LS-28 argenx Japan K.K.				Symposium 24 Advances in Imaging Biomarkers in Multiple Sclerosis				ES-08 Medical Affairs Division, Johnson & Johnson	
Room 15		Symposium 19 Understanding pathogenesis for therapeutic strategy of MG in the future		O-22 Neuromuscular junction disease		LS-29 Tanabe Pharma Corporation				Symposium 25 Considering the co-pathogenesis in neurodegenerative diseases					
Poster Session		Poster Preparation / Poster Viewing					Poster Viewing					Poster Presentation / Discussion		Poster Removal	
Exhibition		Exhibition													

DAY 2

PACIFICO Yokohama Conference Center

PACIFICO Yokohama Exhibition Hall

DAY 3

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Room 1	Main Hall (1F)		Web Symposium 26 Can Chronomedicine Change Neurology Practice?				LS-30 Eli Lilly Japan K.K.	Web PL-02 Plenary Lecture 02 Speaker: Guy Rouleau Chair: Norihiro Suzuki	Web PL-03 AI Plenary Lecture 03 Speaker: Masasumi Nangaku Chair: Kazutoshi Nishiyama	Web 2026 Special Symposium 02 Role of Neurologists in Common Neurological Diseases						
Room 2	301 (3F)		Neuroscience Frontier Symposium 01 Competition and Co-Creation in ALS Drug Development		O-23 Motor neuron disease 3		LS-31 Biogen Japan Ltd.				Neuroscience Frontier Symposium 02 Multidisciplinary comprehensive epilepsy research in the world :from basic, AI to clinical domain					
Room 3	302 (3F)		Web Symposium 27 A New Era in Migraine Management: Multidimensional Approaches		O-24 Headache and Related Neuropathology		LS-32 Alexion Pharma GK				Web Symposium 32 New Trends in the Practice of Functional Neurological Disorders					
Room 4	303 (3F)				O-25 Dementia 2		LS-33 CSL Behring, K.K.				Symposium 33 Old and New Neuro-Ophthalmology - The Forefront of Neuro-Ophthalmology					
Room 5	304 (3F)				O-26 Parkinson's disease 3		LS-34 Sumitomo Pharma Co.,Ltd									
Room 6	311+312 (3F)				O-27 Neuropsychology		LS-35 UCB Japan Co.,Ltd. Medical Affairs									
Room 7	313+314 (3F)				O-28 Neurorehabilitation, Medical engineering, Medical treatment for incurable diseases		LS-36 GlaxoSmithKline K.K.									
Room 8	315 (3F)		Symposium 28 INPH (Hakim's disease) and neurodegenerative diseases: coincidental complications, mutually induced, or single disease entity? How to think and treat?		O-29 Motor neuron disease 4		LS-37 Novartis Pharma K.K.				Symposium 34 Clinical Neuropsychology Challenges: The Role of Cognitive Biomarkers					
Room 9	414+415 (4F)		Symposium 29 Understanding neurological disorders through large-scale genome analysis		O-30 Neuroimmunology 3		LS-38 Eisai Co., Ltd.				Symposium 35 multidisciplinary support for patient with intractable neurological disease					
Room 10	416+417 (4F)		Web AAN From the AAN President to the members of the JSN		O-31 Parkinson's disease 4		LS-39 Cosmic Corporation Co., Ltd.				Web Neuroscience Frontier Symposium 03 Next generation quantitative assessment of neurological symptoms using digital devices					
Room 11	418 (4F)		Symposium 30 Career Pathways for Neurologists in Endovascular Therapy		O-32 Cerebrovascular disease 3		LS-40 Fujirebio Inc.				Symposium 36 New risk factors and treatments for progressive multifocal leukoencephalopathy					
Room 12	419 (4F)		Hot Topics 08 Viruses and Neurodegenerative Diseases: From Novel Pathogenic Insights to Preventive and Therapeutic Strategies		O-33 Neuroimmunology 4		LS-41 T's Pharma Co., Ltd.									
Room 13	501 (5F)		LM-07 Lecture Marathon 07	LM-08 Lecture Marathon 08	O-34 Dementia 3		LS-42 argenx Japan K.K.			LM-09 Lecture Marathon 09	LM-10 Lecture Marathon 10					
Room 14	502 (5F)		New Guideline 03 How to Utilize the Latest "2025 Guidelines for the Diagnosis and Treatment of Polymyositis and Dermatomyositis" for Neurologists		O-35 Muscle disease 2		LS-43 CHUGAI PHARMACEUTICAL CO., LTD.				Symposium 37 Deconstructing Neuropsychiatric Symptoms in Parkinson's disease: from phenomenology to pathophysiology					
Room 15	503 (5F)		Symposium 31 Stroke Oncology, challenges and approach		O-36 Cerebrovascular disease 4		LS-44 Pfizer Japan Inc.				Symposium 38 The actual status of disease modifying anti-tau protein drug					
Poster Session	Hall B (1F)		Poster Preparation / Poster Viewing													
Exhibition			Exhibition												Poster Presentation / Discussion	Poster Removal

PACIFICO Yokohama Conference Center	Room 1	Main Hall (1F)
	Room 2	301 (3F)
	Room 3	302 (3F)
	Room 4	303 (3F)
	Room 5	304 (3F)
	Room 6	311+312 (3F)
	Room 7	313+314 (3F)
	Room 8	315 (3F)
	Room 9	414+415 (4F)
	Room 10	416+417 (4F)
	Room 11	418 (4F)
	Room 12	419 (4F)
	Room 13	501 (5F)
	Room 14	502 (5F)
	Room 15	503 (5F)
Poster Session	Hall B (1F)	
Exhibition	Hall B (1F)	

7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
	O-37 Cerebrovascular disease 5		Web 2026 Special Symposium 03 Anticipations for the Japanese Society of Neurology		LS-45 Eli Lilly Japan K.K.					Change (Genom)				
	O-38 Neuroimmunology 4 (MS · NMO)		Symposium 39 New era of treatment for autoimmune encephalitis and its related disorders		LS-46 AbbVie GK									
	O-39 Motor neuron disease 5		Web Hot Topics 09 Towards the realization of personalized nucleic acid medicine for ultra-rare neurological disorders		LS-47 ONO PHARMACEUTICAL CO., LTD.									
	O-40 Epilepsy		New Guideline 04 Japanese Epilepsy Clinical Guideline 2026		LS-48 Johnson & Johnson Janssen Pharmaceutical K.K.									
	O-41 Neuroimmunology 5				LS-49 Takeda Pharmaceutical Company Limited									
	O-42 Innovative Therapeutics Development and Translational Research				LS-50 FUSHIMI Pharmaceutical Co.,Ltd. / ProteoBridge Corporation									
	O-43 Headache													
	MSO-01 Medical Staff Award Nominee Session		Symposium 40 The role of neurology in medical human resource development: challenges and future perspectives in undergraduate and postgraduate education		LS-51 Otsuka Pharmaceutical Co., Ltd.									
	StO-01 Students and Junior Residents Oral Presentation Award Nominee Session		Symposium 41 Kampo therapy for neurological diseases based on evidence and experience		LS-52 EA Pharma Co., Ltd. / Mochida Pharmaceutical Co., Ltd									
	StO-02 Students and Junior Residents Oral Session 02	StO-05 Students and Junior Residents Oral Session 05	Symposium 42 Support for pediatric-adult healthcare transition in neurological disorders: current status and issues in typical diseases		LS-53 W.L.Gore & Associates G.K.			Web 2026 Special Symposium 04 Launch of the Japanese Association of Clinical Neurologists!						
	StO-03 Students and Junior Residents Oral Session 03	StO-06 Students and Junior Residents Oral Session 06	Symposium 43 Searching for the timekeeping center in the brain		LS-54 TAISHO PHARMACEUTICAL CO., LTD.									
	StO-04 Students and Junior Residents Oral Session 04	StO-07 Students and Junior Residents Oral Session 07												
	O-44 Dementia 4		LM-11 Lecture Marathon 11	LM-12 Lecture Marathon 12	LS-55 UCB Japan Co. Ltd.			LM-13 Lecture Marathon 13	LM-14 Lecture Marathon 14					
	O-45 Cerebrovascular disease 6		Symposium 44 The Beginning of the third five-year plan to overcome stroke and cardiovascular disease: Looking back and looking forward to the future		LS-56 Biogen Japan Ltd.									
	O-46 Parkinson's disease 5		Web Symposium 45 Future-Oriented Prediction of Parkinson's Disease Before Onset		LS-57 Eisai Co., Ltd. Medical HQs / Biogen Japan Ltd., Medical				Resident Clinical Tournament					
			Poster Preparation / Poster Viewing		Poster Viewing	Poster Presentation / Discussion	Poster Removal							
			Exhibition											